Ministry of Health of the Russian Federation, Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products», 2018.

нежелательная реакция, злокачественный нейролептический синдром, полиморфизм гена cyp 2d6, этилметилгидроксипиридина малат, adverse reaction, neuroleptic malignant syndrome, gene polymorphism cyp 2d6, etilmetilgidroksipiridin malat, Therapeutics. Pharmacology, RM1-950

This article provides a retrospective analysis of a case of adverse drug reactions to the drug haloperidol - neuroleptic malignant syndrome. A literature review on the issue of neuroleptic malignant syndrome was represented. The factors that led to this syndrome development of a particular patient were evaluated. Detailed clinical and pharmacological value of gene polymorphism CYP 2D6 is discussed. The data on the successful use of a therapy of neuroleptic malignant syndrome with ethylmethylhydroxypyridine malat are presented.